Por favor, use este identificador para citar o enlazar este ítem:https://uvadoc.uva.es/handle/10324/59878
Título
Modulation of insulin sensitivity by insulin-degrading enzyme
Autor
Año del Documento
2021
Editorial
MDPI
Descripción
Producción Científica
Documento Fuente
Biomedicines, 2021, Vol. 9, Nº. 1, 86
Abstract
Insulin-degrading enzyme (IDE) is a highly conserved and ubiquitously expressed metalloprotease that degrades insulin and several other intermediate-size peptides. For many decades, IDE had been assumed to be involved primarily in hepatic insulin clearance, a key process that regulates availability of circulating insulin levels for peripheral tissues. Emerging evidence, however, suggests that IDE has several other important physiological functions relevant to glucose and insulin homeostasis, including the regulation of insulin secretion from pancreatic β-cells. Investigation of mice with tissue-specific genetic deletion of Ide in the liver and pancreatic β-cells (L-IDE-KO and B-IDE-KO mice, respectively) has revealed additional roles for IDE in the regulation of hepatic insulin action and sensitivity. In this review, we discuss current knowledge about IDE’s function as a regulator of insulin secretion and hepatic insulin sensitivity, both evaluating the classical view of IDE as an insulin protease and also exploring evidence for several non-proteolytic functions. Insulin proteostasis and insulin sensitivity have both been highlighted as targets controlling blood sugar levels in type 2 diabetes, so a clearer understanding the physiological functions of IDE in pancreas and liver could led to the development of novel therapeutics for the treatment of this disease.
Materias (normalizadas)
Insulin
Insulin resistance
Insulina - Receptores
Páncreas
Liver
Liver - Diseases
Glucose
Materias Unesco
32 Ciencias Médicas
2415 Biología Molecular
Palabras Clave
Insulin-degrading enzyme
Enzima degradadora de insulina
ISSN
2227-9059
Revisión por pares
SI
Patrocinador
Ministerio de Economía, Industria y Competitividad - (grant SAF2016-77871-C2-1-R; SAF2016-77871-C2-2-R)
Ministerio de Ciencia e Innovación - (grant PID2019-110496RB-C21; PID2019-110496RB-C22)
Fundación Europea para el Estudio de la Diabetes (Programa Europeo de Investigación de la Diabetes sobre nuevos objetivos para el tipo 2 Diabetes apoyada por MSD-2017)
US National Institutes of Health - (grant GM115617)
Fundación “la Caixa" - (grant LCF/PR/PR18/51130007)
Junta de Castilla y León y Fondo Social Europeo - ((ORDER EDU/574/2018 and ORDER EDU/556/2019)
Ministerio de Ciencia e Innovación - (grant PID2019-110496RB-C21; PID2019-110496RB-C22)
Fundación Europea para el Estudio de la Diabetes (Programa Europeo de Investigación de la Diabetes sobre nuevos objetivos para el tipo 2 Diabetes apoyada por MSD-2017)
US National Institutes of Health - (grant GM115617)
Fundación “la Caixa" - (grant LCF/PR/PR18/51130007)
Junta de Castilla y León y Fondo Social Europeo - ((ORDER EDU/574/2018 and ORDER EDU/556/2019)
Version del Editor
Propietario de los Derechos
© 2021 The authors
Idioma
eng
Tipo de versión
info:eu-repo/semantics/publishedVersion
Derechos
openAccess
Collections
Files in this item
Except where otherwise noted, this item's license is described as Atribución 4.0 Internacional